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Abstract
Grutters et al recently investigated the role of early health economic modelling of health technologies by 
undertaking a secondary analysis of health economic modelling assessments performed by their group. Our 
commentary offers a broad perspective on the potential utility of early health economic modelling to inform 
health technology assessment (HTA) and decision-making around reimbursement of new health technologies. 
Further we provide several examples to compliment Grutters and colleagues’ observations.
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Introduction
Health technology assessment (HTA) is routinely used to 
support reimbursement decisions. The process typically 
involves health economic modelling of available efficacy and 
resource utilisation data on health technologies. However, 
the role is less clear for early health economic modelling to 
identify potentially cost-effective new technologies during 
their development phases; that is, prior to robust efficacy data 
being available. Grutters et al recently investigated this issue 
by undertaking a series of case studies of 32 health economic 
modelling assessments of 30 innovations performed by their 
group.1 There were some limitations to the study, mainly 
stemming from the authors drawing a small sample of 
unpublished HTAs (n = 32) from a single group (their own), 
and considering only the perspective of the Dutch healthcare 
system. Nonetheless, their conclusion that early assessment 
provided insight into the potential cost-effectiveness and 
uncertainty associated with the technology highlights an 
important point: that any intelligence on the future market for 
a new health technology is valuable, not only for its sponsors, 
but also payers as well as providers and patients even though 
the these have different informational needs. 
Early consideration of the cost-effectiveness of a new 
health technology is a logical step, given its prominence in 
reimbursement decisions. The present commentary offers 
a broad perspective on the potential utility of early health 
economic modelling to inform HTA and decision-making 
around reimbursement of new health technologies. 
First, it is important to recognise that there is significant 
variation in HTA requirements from country to country,2,3 and 
not all HTA agencies even require health economic modelling 
to inform decision-making. As such, it can be expected 
that the usefulness of early health economic modelling will 
depend on the market within which it is undertaken, as well 
as the rules for HTA in that market. 
In HTA jurisdictions like Australia, Canada and the United 
Kingdom, there is formal requirement for health economic 
modelling, and although there are well established guidelines 
for undertaking this, there is generally also acceptance of 
novel approaches to accommodate innovative therapies. For 
example, the advent of immuno-oncology agents, which have 
unique biological mechanisms of action and clinical effects, 
has necessitated new approaches to economic evaluation, 
especially with regards to extrapolating and translating data 
beyond the pivotal clinical trials.4 
In countries without mandatory health economic 
modelling, like South Korea and Taiwan, the utility of early 
modelling is less clear. However, this strategy can still be used 
to characterise both the clinical and economic environments 
within which the new health technology will be assessed for 
reimbursement. Insights could be gained into the unmet 
clinical need, the extent to which the health technology would 
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address this, and the price at which this could be done in a 
cost-effective manner. Hence although formal early health 
economic modelling may not be mandated for stop/go 
decisions with respect to reimbursement, the exercise would 
still be very informative.
Regardless of the jurisdiction, there are three key areas 
in which early health economic modelling offers the most 
potential in HTA and reimbursement decision-making: 
identifying uncertainty, assist in the generation of real world 
evidence and informing risk-share agreements.
Minimising Uncertainty
Parameter uncertainty and structural uncertainty in 
economic evaluations is a major problem, and a common 
reason for failure of reimbursement applications.5 Early 
health economic modelling provides a means to identify 
input that will contribute most to the parameter uncertainty 
of a cost-effectiveness analysis. For example, early modelling 
with deterministic or probabilistic sensitivity analyses may 
demonstrate that the relative efficacy (such as the hazard ratio 
associated with an outcome) of the new health technology 
will exert the greatest influence on the likelihood of its cost-
effectiveness, even after taking into account other key input 
parameters. Alternatively, it could identify thresholds in the 
risk of the target disease at which an intervention is most 
likely to be effective, and hence cost-effective and aid in 
calibration of the model structure. This type of information 
could inform the ongoing clinical development of the new 
health technology, and/or recommend further research to 
minimise parameter uncertainty. 
Another common source of uncertainty lies in the long-
term benefits of health technologies. In most HTAs, it is 
necessary to extrapolate outcome data beyond the duration 
of clinical trials, which are typically short (and may be 
surrogate). The Australian Pharmaceutical Benefits Advisory 
Committee (PBAC)6 and the National Institute for Health 
and Care Excellence7 recommend using visual inspection of 
several possible distributions such as the Weibull, loglogistic, 
lognormal, Gompertz and exponential as well as comparisons 
of the Akaike information criteria (AIC) when choosing 
distributions for extrapolations. The guidelines stipulate that 
the distribution with lowest AIC score should be chosen. 
The AIC is agnostic to the underlying behavior in the 
data and the mathematical properties of the distributions. 
Sometimes the AIC values can be almost identical as 
reported by Bohensky et al8 where the AIC for the Weibull 
distribution was observed to be 243.204 and 243.451 for the 
loglogistic distribution in the post progression health state. 
This equates to a 0.1% difference but more importantly the 
two distributions are fundamentally different. The Weibull 
distribution is monotone and the hazard cannot change 
direction. This means that if an increasing hazard (eg, risk 
of death) is assumed then it will keep increasing over time. 
The loglogistic distribution on the other hand allows for 
the hazard to change direction over time.9,10 For some of the 
immune-oncology drugs it is well-known11 that after an initial 
steep drop in the survival curve there is a plateau like effect 
meaning that the hazard increases to begin with but then 
decreases after a while. 
Early modelling would be able to assist in validating the 
behavior of the hazard and guide modelers in the choice of 
distribution instead of relying on measures like the AIC.
Another issue is time horizon of the extrapolation. For 
example, in Australia, trastuzumab for patients with HER2 
positive early breast cancer following surgery in association 
with chemotherapy was considered for reimbursement by the 
PBAC in July 2006. The sponsor had extrapolated outcome 
data from the clinical trial over a 40-year time horizon, but 
not detailed the methods for extrapolation.12 This was a 
major source of uncertainty. There were no explicit guidelines 
regarding the extrapolation of observed data but this was a 
major source of uncertainty. However, since then, the topic has 
been widely debated13,14 and current guidelines now mandate 
rigorous examination of extrapolation methods.6 Had early 
health economic modelling been undertaken as part of the 
HTA for trastuzumab, the multiple sources of uncertainty 
would have been identified, including timeframes over which 
efficacy measures could have been assumed, the various 
functions that could have been fit to extrapolate survival data, 
and the impact of decreasing adherence over time.
Underlying uncertainty relating to the structure of the model 
(structural uncertainty) such as how health states are linked in 
a Markov model or choice of underlying survival functions in 
a partitioned survival model can also be minimised through 
early health economic modelling. This can be done by 
ensuring that economic models are set up in flexible ways to 
allow for testing of different scenarios. These scenarios could 
relate to key structural assumptions that are not normally 
taken tested in models such as Markovian assumptions 
surrounding time dependent transition probabilities, or 
what time point to apply extrapolation to Kaplan Meier data 
in partitioned survival models. Key to this is the mapping 
of future treatment pathways for the particular diseases of 
interest. Predicting future treatment pathways is challenging, 
but achievable with available data and expertise. For example, 
a review of clinical trial registries like www.clinicaltrials.gov 
and the convening of expert advisory panels are both useful. 
It is important to note that future comparators may not be the 
same modality; for example, what is a drug comparator now 
may be a device in the future.
Generation of Real-World Data
The use of real-world data is an area of major increasing 
interest in HTA.15 Early health economic modelling uses 
real-world data in conjunction with clinical trial data, and 
is potentially a useful tool that can used to aid and guide 
gathering of real world data. An example of real-world data 
and early modelling guiding decision-making can be found 
in the work by Tappenden et al in 2017.16 Here, registry data, 
evidence drawn from the literature and expert opinion were 
used to populate an early model on an adherence intervention 
to improve outcomes for patients with cystic fibrosis. The 
analysis allowed for estimation of health gains and expected 
costs savings over a five-year period and the study is still 
ongoing. 
Clinical trials are typically designed with the aim of 
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obtaining regulatory approval for the health technology, not 
reimbursement approval. Moreover, due to patient selection 
and strict protocols, clinical trials can often overestimate an 
interventions effect when implemented into clinical practice. 
Thus, a major issue in HTA is whether efficacy data from 
a clinical trial translates into real-world effectiveness.17 
Early modelling is a vehicle for translating and synthesizing 
efficacy data from early phase clinical trials into real-
world effectiveness data and can therefore support future 
reimbursement decisions. A major advantage of modelling 
is that multiple and complex scenarios can be explored with 
currently available modelling techniques. For example, agent-
based systems can take into consideration that many clinicians 
do not prescribe drugs exactly as per reimbursement criteria, 
and patients are often not compliant with the intended 
regimen.18 Other examples include dynamic simulation of 
systems and discrete event simulations.19
Furthermore, early health economic modelling could 
aid the generation of real-world data when no other data 
are available. This would typically be the case when clinical 
trials have not yet been reported. Real-world data such as 
clinical registries, patient charts and script data can easily be 
synthesised using a health economic model. This would then 
enable additional research recommendations to be based on 
many different types of evidence particularly health resource 
utilisation data, which is often protocol driven in clinical 
trials. 
Risk Share Agreements
There is currently increased focus on how to accelerate access 
to new health technologies. Initiatives include streamlining 
processes between regulatory and HTA authorities,20 as well as 
through harmonisation initiatives like the European Network 
for Health Technology Assessment.21 Moreover, there seems 
to be a tendency for payers to be to prepared to enter into 
‘coverage with evidence’ development schemes or risk share 
agreements.4,22 This is typically done in order to acquire 
further data to support the evidence for the incremental cost-
effectiveness ratio. Unfortunately, while these schemes and 
agreements offer a solution to early funding as reimbursement 
is granted even though evidence such as mature survival data 
is not yet available, the risks are often not well-understood.23,24 
Early health economic modelling could bridge this gap by 
better conceptualising the risks and uncertainties for both 
payers and sponsors.
Early modelling would have been valuable in the high 
unmet need case of ipilimumab for advanced melanoma in 
Australia. After three failed initial applications by the sponsor 
for reimbursement, the Australian PBAC finally granted 
coverage of ipilimumab under a condition that the sponsor 
to provide future evidence of improved overall survival.25 A 
post marketing follow-up program was established and the 
overall survival claim was verified.26 Early health economic 
modelling with input from the payer could have identified 
the overall survival claim as a major issue up front, thereby 
avoiding multiple submissions.
Many risk share agreements are still financial in nature,27 
which is another area where early modelling can be valuable. 
For example, the Australian PBAC determined that a 
financial risk share agreement for pembrolizumab in first line 
treatment of non-small cell lung cancer was needed.28 A 100% 
rebate beyond a subsidisation cap was proposed to mitigate 
the overall budgetary risk to the government if the number of 
actual patients exceeded that which was agreed upon. Early 
economic modelling could have been used to inform the 
budget modelling and subsequently offer alternatives to this 
arrangement, in which all the risk is carried by one party. 
Conclusion
Early health economic modelling provides a mechanism for 
early assessment of new health technologies, as pointed out 
by Grutters et al. Its acceptance and utility will depend on the 
environment and context within which it is undertaken, but 
minimising uncertainty, generation of real-world evidence 
and informing risk share agreements stand out as areas of 
greatest potential. There is unfortunately a lack of literature 
demonstrating the power of early modelling and researchers 
from academia and industry are encouraged to publish more 
papers describing health economic modelling before/during/
after development of health technologies.
It would be surprising if pharmaceutical and device 
industry did not already use early modelling in some form 
to inform development of their products.29 However, through 
wider collaboration with stakeholders and payers, early health 
economic modelling could be instrumental in bridging the 




Authors declare that they have no competing interests. 
Authors’ contributions
All authors contributed to the conception, drafting and approval of manuscript. 
Authors’ affiliations
1School of Public Health and Preventive Medicine, Monash University, Melbourne, 
VIC, Australia. 2Centre for Health Economics Research and Evaluation, University 
of Technology Sydney, Ultimo, NSW, Australia. 
References
1. Grutters JPC, Govers T, Nijboer J, Tummers M, van der Wilt GJ, 
Rovers MM. Problems and promises of health technologies: the 
role of early health economic modeling. Int J Health Policy Manag. 
2019;8(10):575-582. doi:10.15171/ijhpm.2019.36
2. Sarnes E, Cadarette SM, Sawchyn B, et al. A Comparison of Health 
Technology Assessment (HTA) Requirements For Systematic 
Literature Reviews (SLRS). Value Health. 2017;20(9):A698. 
doi:10.1016/j.jval.2017.08.1799
3. Allen N, Liberti L, Walker SR, Salek S. A comparison of reimbursement 
recommendations by European HTA agencies: is there opportunity 
for further alignment? Front Pharmacol. 2017;8:384. doi:10.3389/
fphar.2017.00384
4. Kim H, Goodall S, Liew D. Health technology assessment 
challenges in oncology: 20 years of value in health. Value Health. 
2019;22(5):593-600. doi:10.1016/j.jval.2019.01.001
5. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using 
effectiveness and cost-effectiveness to make drug coverage 
decisions: a comparison of Britain, Australia, and Canada. JAMA. 
2009;302(13):1437-1443. doi:10.1001/jama.2009.1409
6. Australian Government Department of Health. Guidelines for 
Kim et al
International Journal of Health Policy and Management, 2020, x(x), 1–44
Preparing Submissions to the Pharmaceutical Benefits Advisory 
Committee. Australian Government Department of Health; 2015.
7. Latimer N. NICE DSU Technical Support Document 14: Survival 
Analysis for Economic Evaluations Alongside Clinical Trials-
Extrapolation with Patient-Level Data. http://nicedsu.org.uk/
wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.
updated-March-2013.v2.pdf. Published 2013.
8. Bohensky MA, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew 
D. A cost-effectiveness analysis of nivolumab compared with 
ipilimumab for the treatment of BRAF wild-type advanced melanoma 
in Australia. Value Health. 2016;19(8):1009-1015. doi:10.1016/j.
jval.2016.05.013
9. Hougaard P. Analysis of Multivariate Survival Data. New York, USA: 
Springer-Verlag; 2000.
10. Collett D. Modelling Survival Data in Medical Research. Florida, 
USA: Chapman & Hall/CRC; 2003.
11. Gibson E, Koblbauer I, Begum N, et al. Modelling the survival 
outcomes of immuno-oncology drugs in economic evaluations: 
a systematic approach to data analysis and extrapolation. 
Pharmacoeconomics. 2017;35(12):1257-1270. doi:10.1007/
s40273-017-0558-5
12. Australian Government PBAC. Public summary document: 
trastuzumab for HER2 positive breast cancer. http://www.pbs.
gov.au/info/industry/listing/elements/pbac-meetings/psd/2006-07/
trastuzumab. 2006.
13. Latimer NR. Survival analysis for economic evaluations alongside 
clinical trials--extrapolation with patient-level data: inconsistencies, 
limitations, and a practical guide. Med Decis Making. 2013;33(6):743-
754. doi:10.1177/0272989x12472398
14. Bullement A, Meng Y, Cooper M, et al. A review and validation of 
overall survival extrapolation in health technology assessments of 
cancer immunotherapy by the National Institute for Health and Care 
Excellence: how did the initial best estimate compare to trial data 
subsequently made available? J Med Econ. 2019;22(3):205-214. 
doi:10.1080/13696998.2018.1547303
15. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins 
CD. Using real-world data for coverage and payment decisions: 
the ISPOR Real-World Data Task Force report. Value Health. 
2007;10(5):326-335. doi:10.1111/j.1524-4733.2007.00186.x
16. Tappenden P, Sadler S, Wildman M. An early health economic 
analysis of the potential cost effectiveness of an adherence 
intervention to improve outcomes for patients with cystic fibrosis. 
Pharmacoeconomics. 2017;35(6):647-659. doi:10.1007/s40273-
017-0500-x
17. Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and 
efficacy trials. Clin Transl Gastroenterol. 2014;5:e45. doi:10.1038/
ctg.2013.13
18. Tracy M, Cerda M, Keyes KM. Agent-based modeling in public health: 
current applications and future directions. Annu Rev Public Health. 
2018;39:77-94.  doi:10.1146/annurev-publhealth-040617-014317
19. Marshall DA, Burgos-Liz L, IJzerman MJ, et al. Applying dynamic 
simulation modeling methods in health care delivery research-the 
SIMULATE checklist: report of the ISPOR simulation modeling 
emerging good practices task force. Value Health. 2015;18(1):5-16. 
doi:10.1016/j.jval.2014.12.001
20. Cook G, Kim H. From regulatory approval to subsidized patient 
access in the Asia-Pacific region: a comparison of systems 
across Australia, China, Japan, Korea, New Zealand, Taiwan, and 
Thailand. Value Health Reg Issues. 2015;6:40-45. doi:10.1016/j.
vhri.2015.03.013
21. European Commission. Proposal for a regulation of the European 
Parliament and of the Council on health technology assessment and 
amending Directive 2011/24/EU. https://ec.europa.eu/health/sites/
health/files/technology_assessment/docs/com2018_51final_en.pdf. 
Published 2018.
22. Tuffaha HW, Scuffham PA. The Australian managed entry scheme: 
are we getting it right? Pharmacoeconomics. 2018;36(5):555-565. 
doi:10.1007/s40273-018-0633-6
23. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing 
arrangements for pharmaceuticals: potential considerations and 
recommendations for European payers. BMC Health Serv Res. 
2010;10:153. doi:10.1186/1472-6963-10-153
24. Vitry A, Roughead E. Managed entry agreements for pharmaceuticals 
in Australia. Health Policy. 2014;117(3):345-352. doi:10.1016/j.
healthpol.2014.05.005
25. Australian Government PBAC. Public Summary Document: 
Ipilimumab - November 2012. http://www.pbs.gov.au/info/industry/
listing/elements/pbac-meetings/psd/2012-11/ipilimumab. Published 
2012.
26. Kim H, Comey S, Hausler K, Cook G. A real world example of 
coverage with evidence development in Australia - ipilimumab 
for the treatment of metastatic melanoma. J Pharm Policy Pract. 
2018;11:4. doi:10.1186/s40545-018-0131-4
27. Gonçalves FR, Santos S, Silva C, Sousa G. Risk-sharing 
agreements, present and future. Ecancermedicalscience. 
2018;12:823. doi:10.3332/ecancer.2018.823
28. Australian Government PBAC. Public Summary Document: 
Pembrolizumab (NSCLC) July 2018. http://www.pbs.gov.au/pbs/in-
dustry/listing/elements/pbac-meetings/psd/2018-07/Pembrolizum-
ab-Keytruda-psd-july-2018. Published 2018.
29. IJzerman MJ, Koffijberg H, Fenwick E, Krahn M. Emerging use of 
early health technology assessment in medical product development: 
a scoping review of the literature. Pharmacoeconomics. 
2017;35(7):727-740. doi:10.1007/s40273-017-0509-1
